Gracell Biotechnologies/GRCL

$10.25

0.05%
-
1D1W1MYTD1YMAX

About Gracell Biotechnologies

Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The Company is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.

Ticker

GRCL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Wei Cao

Employees

314

Headquarters

Shanghai, China

GRCL Metrics

BasicAdvanced
$990.82M
Market cap
-
P/E ratio
-$0.99
EPS
-
Beta
-
Dividend rate
$990.82M
$10.44
$1.40
1.32M
7.732
2.069
6.592
-26.66%
-31.57%
-30.56%
4.359
4.395
20.34%

What the Analysts think about GRCL

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 6 analysts.
3.22% upside
High $11.50
Low $10.00
$10.25
Current price
$10.58
Average price target

GRCL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
¥0
-
Net income
¥-67.6M
-53.98%
Profit margin
0%
-

GRCL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 49.15%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.30
-$0.35
-$0.30
-$0.10
-
Expected
-$0.17
-$0.40
-$0.40
-$0.20
-$0.14
Surprise
77.67%
-11.39%
-25%
-49.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Gracell Biotechnologies stock?

Gracell Biotechnologies (GRCL) has a market cap of $990.82M as of April 23, 2024.

What is the P/E ratio for Gracell Biotechnologies stock?

The price to earnings (P/E) ratio for Gracell Biotechnologies (GRCL) stock is 0 as of April 23, 2024.

Does Gracell Biotechnologies stock pay dividends?

No, Gracell Biotechnologies (GRCL) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Gracell Biotechnologies dividend payment date?

Gracell Biotechnologies (GRCL) stock does not pay dividends to its shareholders.

What is the beta indicator for Gracell Biotechnologies?

Gracell Biotechnologies (GRCL) does not currently have a Beta indicator.

What is the Gracell Biotechnologies stock price target?

The target price for Gracell Biotechnologies (GRCL) stock is $10.58, which is 3.22% above the current price of $10.25. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Gracell Biotechnologies stock

Buy or sell Gracell Biotechnologies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing